SUPN Supernus Pharmaceuticals Inc.

21.96
-0.95  -4%
Previous Close 22.91
Open 22.86
Price To Book 2.07
Market Cap 1,152,086,075
Shares 52,462,936
Volume 766,861
Short Ratio
Av. Daily Volume 692,401
Stock charts supplied by TradingView

NewsSee all news

  1. Supernus to Present at Two November Healthcare Conferences

    ROCKVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

    ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  3. Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

    Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating earnings of $39.7 million, compared to $37.5

  4. Supernus to Host Third Quarter 2019 Earnings Conference Call

    ROCKVILLE, Md., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  5. Supernus to Present at the 2019 Cantor Global Healthcare Conference

    ROCKVILLE, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
NDA filing announced November 11, 2019.
SPN-812 (P301)
ADHD
Phase 3 trial did not meet primary endpoint - November 5, 2019.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine
FDA approval announced December 14, 2018 to expand label to include monotherapy treatment.
Oxtellar XR
Epilepsy
Phase 3 data trial to be initiated 4Q 2019.
SPN-604
Bipolar depression
Phase 3 data due by the end of 2019.
SPN-810 (P302)
Attention Deficit Hyperactivity Disorder (ADHD)

Latest News

  1. Supernus to Present at Two November Healthcare Conferences

    ROCKVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  2. Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

    ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  3. Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

    Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating earnings of $39.7 million, compared to $37.5

  4. Supernus to Host Third Quarter 2019 Earnings Conference Call

    ROCKVILLE, Md., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  5. Supernus to Present at the 2019 Cantor Global Healthcare Conference

    ROCKVILLE, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

  6. Supernus to Present at Two September Healthcare Conferences

    ROCKVILLE, Md., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system